Name: ABCIXIMAB (ReoproR) Classification: platelet glycoprotein IIb/IIIa receptor antagonist (human monoclonal antibody) inhibits platelet aggregation used with heparin and aspirin as adjunct to percutaneous transluminal coronary angioplasty Dose: IV Direct: 0.25mg/kg over at least 1 minute given 10-60 minutes before the procedure Administration: IV Infusion: 9 mg / 250 ml sodium chloride 0.9% run at 10 ug/min for 12 hours post cardiac catheterization should be administered with a 0.2 micron filter requires dedicated line Adverse Effects: Hematological: risk for complications increase in patients over 65 years, with history of GI disease or who weigh less than 75 kg major bleeding incidents (intracranial, GI or retroperitoneal characterized by abdominal, back or leg pain) thrombocytopenia anemia, leukocytosis Cardiovascular: arrhythmias hypotension pericardial effusion, peripheral edema Respiratory: pleural effusion, pericarditis pulmonary edema pulmonary embolism pneumonia Other: nausea, vomiting visual distrubances Contraindications: active hemorrhage active intracranial or gastrointestinal bleeding severe hypertension history of vasculitis underlying condition and risk for bleeding must be weight against potential benefits Caution: readministration within 30 days is asoociated with more severe thrombocytopenia Monitoring Therapy: INR/PTT hemoglobin platelet count bleeding continuous heart rate and ECG rhythm blood pressure Adult Critical Care Protocol: May be administered IV direct or by IV infusion by an Adult Critical Care Nurse. Continuous infusions must be administered by infusion device and the pump library must be enabled. Lynne Kelly, Pharmacist, CCTC Brenda Morgan, Clinical Nurse Specialist, CCTC Last Update: September 17, 2018
